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Abstract
Background The Bravo capsule allows monitoring of
esophageal acid exposure over a two-day period. Experi-
ence has shown that 24–32% of patients will have abnor-
mal esophageal acid exposure detected on only one of the
2 days monitored. This variation has been explained by the
effect of endoscopy and sedation. The aim of this study was
to assess the day-to-day discrepancy following transnasal
placement of the Bravo capsule without endoscopy or
sedation and to determine factors related to this variability.
Methods Bravo pH monitoring was performed by trans-
nasal placement of the capsule in 310 patients. Patients
were divided into groups based on the composite pH score:
both days normal, both days abnormal and only one of the
2 days abnormal. Lower esophageal sphincter (LES)
characteristics were compared between groups.
Results Of the 310 patients evaluated, 60 (19%) showed a
discrepancy between the 2 days. A total of 127 patients had
a normal pH score on both days and 123 had an abnormal
pH score on both days. Of the 60 patients with a discrep-
ancy, 27 were abnormal the ﬁrst day and 33 (55%) were
abnormal the second day. Patients with abnormal
esophageal acid exposure on both days had higher degrees
of esophageal acid exposure and were more likely to have a
defective LES compared to those with an abnormal score
on only one day (35 vs. 83%, p = 0.027).
Conclusion Patients with a discrepancy between days of
Bravo pH monitoring have lower esophageal acid expo-
sure. Variability between the 2 days represents early
deterioration of the gastroesophageal barrier and indicates
less advanced reﬂux disease.
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The Bravo pH capsule (Given Imaging Inc., Duluth, GA) is
a catheter-free system for ambulatory esophageal pH
monitoring. An advantage of this system compared to a
traditional nasoesophageal catheter is that it is more patient
friendly and therefore allows measurement of esophageal
acid exposure over a 48-h period. Previous reports have
shown that 24-32% of patients have a discrepancy in acid
exposure between the ﬁrst and second 24-h monitoring
periods [1–3]. It has been postulated that this discrepancy is
related to the sedation used during endoscopic placement
of the Bravo capsule, which may cause increased acid
exposure early in the ﬁrst 24-h monitoring period [4]. An
alternative hypothesis is that some patients with gastro-
esophageal reﬂux disease (GERD) may have day-to-day
variability in the amount of esophageal acid exposure. This
hypothesis is supported by studies using the nasoesopha-
geal pH catheter that showed a similar degree of discrep-
ancy on repeated 24-h pH tests [5]. The aim of this study
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DOI 10.1007/s00464-010-1529-5was to assess the discrepancy in acid exposure measured on
day 1 and day 2 of Bravo pH monitoring following trans-
nasal insertion and manometric placement of the pH cap-
sule and to determine factors associated with this
variability.
Materials and methods
From 2003 to 2007, 475 patients referred for evaluation of
symptoms of GERD underwent ambulatory pH monitoring
using the Bravo capsule. The study population included
patients with no history of foregut surgery who had the
Bravo pH capsule placed transnasally without sedation and
who were monitored while off acid suppression therapy. A
total of 310 patients met these criteria.
Esophageal manometry
All patients underwent esophageal manometry using a
previously described technique [6]. In brief, a 12-French
8-channel water-perfused motility catheter (Arndorfer
Medical Specialties, Greendale, WI) was passed through
the anesthetized nostril after an overnight fast and the
position of the lower esophageal sphincter (LES) in cen-
timeters from the nostril was recorded using a commer-
cially available software program (Polygram Net,
Medtronic Inc., Minneapolis, MN). Three manometric
characteristics of the LES were assessed: resting pressure,
total length, and abdominal length. The LES was consid-
ered defective when any or all of these components were
abnormal [7].
Technique of measuring esophageal acid exposure
Patients were instructed to discontinue proton pump
inhibitor medication 14 days and H2 blocker medication
3 days prior to pH monitoring and to avoid antacid medi-
cations during the study period. After an overnight fast, the
Bravo delivery device and the attached pH capsule were
inserted through an anesthetized nostril into the esophagus.
The pH capsule was advanced into the stomach to measure
gastric pH and then pulled back into the esophagus and
deployed 5 cm above the manometrically determined
upper border of the LES. Patients were asked to maintain a
diary of symptoms and to record the time that they retired
into bed in the evening and when they arose in the morn-
ing. They were instructed to remain in the upright or sitting
position until retiring to bed in the evening and to lie ﬂat at
night if possible. They were asked to go about their normal
duties at home or work. They were to refrain from eating or
drinking between meals and avoid chewing gum and
smoking. One meal during the study was standardized and
consisted of a hamburger, fries, and milkshake obtained at
a fast-food restaurant. The other meals were chosen from a
list of foods with a pH between 5 and 7. The meals were to
be consumed at one sitting and accompanied only by water,
milk, coffee, or tea. Carbonated beverages, alcohol, and
fruit drinks with a low pH were not allowed. At the end of
the recording period the data were downloaded from the
recording unit to a personal computer for analysis using a
commercially available software program (Polygram
 Net,
Medtronic Inc., Minneapolis, MN). Components of pH
measurements and a composite pH score were used to
express esophageal acid exposure [8].
Data analysis and statistical methods
Values are reported as median and interquartile range
(IQR) unless otherwise indicated. Nonparametric tests
were used to compare continuous variables and the v
2 test
was used to compare categorical variables. The Spearman
test was used to assess correlation, expressed as the cor-
relation coefﬁcient R with 95% conﬁdence intervals (CI). A
p value of less than 0.05 was considered statistically sig-
niﬁcant. Statistical analyses were performed using Prism 4
statistical software (Graphpad, San Diego, CA).
Results
The study population consisted of 158 males and 152
females with a median age of 52 years (IQR: 42–63).
Esophageal acid exposure measured by Bravo pH moni-
toring on day 1 and day 2 are compared in Table 1.
Overall, there were no signiﬁcant differences between day
1 and day 2 in any of the components or the composite pH
score. There was good correlation between acid exposure
measured on day 1 and day 2 for % total time pH\4 and
the composite pH score (Fig. 1). The composite pH score
was normal on both days in 127 patients (41%) and
abnormal on both days in 123 patients (40%). The score
was abnormal on only one of the 2 days in 60 patients
(19%). In patients who were abnormal on only 1 day, 55%
had the abnormal composite pH score on the second day. In
patients who were abnormal on both days, the composite
pH score was higher on day 2 in 54%. These differences
were not statistically signiﬁcant (p = 0.71 and p = 0.70,
respectively).
To evaluate the severity of reﬂux in patients with an
abnormal composite pH score on only 1 day and those with
an abnormal pH score on both days, we compared the
frequency of abnormality for each of the components of pH
monitoring and the individual values for these components
from the worst day of reﬂux, deﬁned as the day with the
highest composite pH score. Patients who had an abnormal
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123score on both days had a higher frequency of abnormality
for each of the individual components (Fig. 2) and more
severe reﬂux conﬁrmed by each of the six components and
the composite pH score (Table 2). Patients were divided
into ten groups of equal size (31 in each group) based on
the composite pH score on day 1, and the percentage of
patients with a discrepancy between day 1 and day 2 is
plotted in Fig. 3. Patients with a composite pH score less
than 8.7 and greater than 19.3 on day 1 had a low likeli-
hood of discrepancy.
There was a progressive decrease in LES length and
resting pressure starting with patients who were normal on
both days, followed by those who were abnormal on only
1 day, and ending with those who were abnormal on both
days (Table 3). There was also a progressive increase in the
prevalence of a defective LES (Fig. 4) and the number of
defective components (Table 4) when patients who were
normal on both days, those who were abnormal on only
1 day, and those who were abnormal on both days were
compared.
Discussion
Ambulatory pH monitoring when properly performed is a
critical tool in the management of patients suspected of
having GERD. Until recently this required a pH catheter
placed through the nose for 24 h causing discomfort, social
embarrassment, and restriction of patient activity during
the monitored periods [9]. This could lead to underesti-
mation of the amount of esophageal acid exposure that
would occur under more typical lifestyle circumstances.
With the introduction of the catheter-free Bravo pH
Table 1 Comparison of esophageal acid exposure on day 1 and day 2
in all patients (n = 310)
Day 1 Day 2 p value
a
% Total time pH\4 3.7 (1.0–9.9) 4.5 (0.9–9.7) 0.1679
% Upright time pH\4 4.5 (1.2–12.1) 4.8 (1.0–11.5) 0.5238
% Supine time pH\4 0.3 (0.0–5.9) 0.3 (0.0–6.30) 0.4963
Number of reﬂux
episodes
39 (13–74) 36 (14.5–76) 0.5746
Number of episodes
C5 min
2 (0–7) 2 (0–7) 0.3869
Longest reﬂux episode
(min)
10 (3–25) 9.0 (3.0–21.5) 0.3006
Composite pH score 13.1 (4.7–32.0) 14.4 (3.9–30.5) 0.6552
a Wilcoxon matched pairs test
Fig. 1 Correlation between day 1 and day 2 for A % total time pH\4
and B composite pH score. The Spearman R correlation coefﬁcients
were 0.94 (95% CI = 0.93-0.95, p\0.0001) and 0.83 (95%
CI = 0.79-0.86, p\0.0001), respectively
Fig. 2 Frequency of an abnormal component on the worst day of
reﬂux in patients with a positive score on only one day and those with
a positive score on both days. There was a signiﬁcant difference for
each individual component (p\0.01,*p\0.05, Fisher’s exact test)
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123capsule, these limitations are avoided. Patients have no
social embarrassment, less discomfort, and less interfer-
ence with activities of daily living [1].
These advantages of the Bravo capsule allow monitoring
of esophageal pH for longer periods of time. In practice,
patients are commonly monitored for 48 h and esophageal
acid exposure is calculated separately for the ﬁrst and
second day and for the combined 48 h. Clinical experience
has shown that approximately 25–30% of patients will
have abnormal esophageal acid exposure detected on only
one of the 2 days of monitoring [1-3]. Our previous work
has shown that patients who have an abnormal composite
pH score on either day should be considered to have
increased esophageal acid exposure and reﬂux disease [10].
The reason for a discrepancy between the 2 days of
monitoring is incompletely understood. One proposed
explanation is that endoscopy and sedation encourage
reﬂux [11]. Because of this, it has been suggested that the
ﬁrst 6 h of recording after sedation and endoscopic place-
ment of the pH capsule should be excluded [4]. With this
exclusion, Bhat et al. [4] reported better agreement of the
results of the 2 days of monitoring but there were still a
signiﬁcant number of patients with a discrepancy in the
results on day 1 and day 2. It appears that their rate of
discrepancy after excluding the ﬁrst 6 h is similar to the
19% rate of discrepancy in our series of patients who had
the capsule placed transnasally without sedation. An
alternative explanation is that there are differences in the
severity of reﬂux disease between patients who are
abnormal on only 1 day and those who are abnormal on
both days. Our results support this hypothesis. Patients who
were abnormal on only 1 day had lower levels of esopha-
geal acid exposure by all components measured, and their
composite pH score was also signiﬁcantly lower (21 vs. 50)
when compared to those who were abnormal on both days.
Table 2 Comparison of the
worst day of reﬂux between
patients with an abnormal
composite score on only one
day and those with an abnormal
score on both days
* Mann–Whitney U test
Components Abnormal score on
one day (n = 60)
Abnormal score on
both days (n = 123)
p value*
% Total time pH\4 6.3 (4.7–8.2) 15.1(10.2–21.4) \0.0001
% Upright time pH\4 7.3 (4–9.8) 15.6 (9.6–23.2) \0.0001
% Supine time pH\4 4.6 (0.2–7.6) 14.1 (3–28.2) \0.0001
Number of reﬂux episodes 46 (29–65) 91.5 (65.5–136) \0.0001
Number of episodes C 5 min 3 (2–6) 10 (6–14) \0.0001
Longest reﬂux episode (min) 17.5 (12–35.5) 28.5 (16.5–95) 0.0004
Composite pH Score 20.7 (16.5–26.3) 50.2 (30.5–69) \0.0001
Fig. 3 The proportion of the patients who had a discrepancy between
day 1 and day 2. Patients were divided into ten groups of equal size
(31 in each group) based on the composite pH score on day 1, and the
percentage of patients with a discrepancy between day 1 and day 2 is
plotted. Fifty-one percent of patients with a pH score between 8.7 and
19.3 on the ﬁrst day had a discrepancy between day 1 and day 2. In
contrast, of those who had a pH score of\8.7 or[19.3 on their ﬁrst
day of monitoring, only 11% had a day-to-day discrepancy
Table 3 Resting characteristics
of the LES (n = 310)
* Kruskal–Wallis test
Normal score on
both days (n = 127)
Abnormal score on
one day (n = 60)
Abnormal score on
both days (n = 123)
p value*
Overall length (cm) 2.9 (2.4–3.6) 2.7 (2.2–3.4) 2.3 (1.6–3.2) 0.0002
Abdominal length (cm) 1.8 (1.4–2.3) 1.6 (1.0–2.0) 1.2 (0.8–1.8) \0.0001
Resting pressure (mmHg) 14.9 (10.2–23.7) 13.7 (8.7–18.3) 9.2 (5.5–15.0) \0.0001
Fig. 4 The prevalence of a defective LES in patients with a normal
score on both days (17%), an abnormal score on only one day (35%),
and an abnormal score on both days (83%) (p\0.0001 across all
three groups)
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123These ﬁndings are consistent with the observations of
Wiener et al. [5] who performed repeat catheter-based 24-h
esophageal pH monitoring. They found that there was a
low probability of inconsistent results between the two
monitoring periods in normal subjects and in those with
severe reﬂux disease (deﬁned as a total time pH\4 above
9.4%), but in patients with milder degrees of reﬂux there
was a higher probability of having inconsistent results [5].
In our series, the highest likelihood of a discrepancy
between day 1 and day 2 occurred in patients with a pH
score on the ﬁrst day between 8.7 and 19.3, where 51% had
a discrepancy. Patients with milder degrees of reﬂux and
those with the most severe reﬂux were much less likely
(11%) to have a discrepancy between day 1 and day 2.
In addition to having less severe reﬂux disease, patients
with a discrepancy between the 2 days of Bravo monitoring
alsohadlessseverephysiologicabnormalitiesonmanometry.
The overall length of the LES and the resting LES pressure
were signiﬁcantly greater in patients who were abnormal on
only 1 day compared to patients who were abnormal on both
days.Furthermore,patientsthatwereabnormalononly1 day
were more likely to have a manometrically normal LES
compared to those who were abnormal on both days.
In conclusion, when Bravo pH monitoring is performed
with transnasal placement of the pH capsule, thus elimi-
nating the effect of endoscopy and sedation, a discrepancy
between the results measured on day 1 and day 2 is less but
still exists. Factors associated with this discrepancy are the
severity of the esophageal acid exposure and the degree of
competency of the lower esophageal sphincter. Variability
between the 2 days of monitoring represents early deteri-
oration of the gastroesophageal barrier and indicates less
advanced reﬂux disease.
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